@article{Ciociola_Colpi_2013, title={Peyronie’s disease: A “triple oxygenant therapy”}, volume={85}, url={https://www.pagepressjournals.org/aiua/article/view/aiua.2013.1.36}, DOI={10.4081/aiua.2013.1.36}, abstractNote={Objectives: To evaluate the effects of upregulators of nitric oxide in one patient with Peyronie’s disease, after non significant improvement following intracavernosal verapamil. Methods: A 20-years-old Caucasian male presented with penile induration in flaccid state, persistent during erection and associated with mild pain at third middle of penis. After treatment with intracavernosal verapamil for 4 months with relief of penile discomfort, followed by counseling on the use of penile extender for at least 6 hours per day, he was prescribed pentoxifylline associated with tadalafil plus levo-arginine, propionil-carnitine and Vitamin B3. Results: After almost 2 years, the septal thickness was reduced at ultrasound evaluation after this “triple oxygenant therapy”. Conclusion: NO-iNOS biology in Peyronie patients is the very protagonist in modulating penile fibrosis through up-regulation of NO-cGMP pathway that influences penile health by preventing and reversing fibrosis in the tunical albuginea.}, number={1}, journal={Archivio Italiano di Urologia e Andrologia}, author={Ciociola, Francesco and Colpi, Giovanni Maria}, year={2013}, month={Apr.}, pages={36–40} }